肽类药物市场机会、成长驱动因素、产业趋势分析及预测（2025-2034年）

2024 年全球胜肽类药物市场价值为 464 亿美元，预计到 2034 年将以 8.1% 的复合年增长率增长至 1000 亿美元。

慢性病和生活型态相关疾病（包括糖尿病、癌症和肥胖症）的日益普遍是推动胜肽类药物市场成长的重要因素。肽类药物由短链胺基酸组成，针对特定的分子通路，与传统疗法相比，具有更高的疗效和更低的副作用。这些疗法已应用于多种治疗领域，例如代谢失调、心血管疾病、胃肠道疾病、传染病、癌症和罕见遗传疾病。电子健康记录、基于人工智慧的临床决策工具和真实世界证据平台的整合正在重塑胜肽类药物的研发、监测和处方模式。政府计画和公私合作计画提高了分子诊断、个人化医疗和罕见疾病治疗的可及性，进一步加速了胜肽类药物市场的成长。随着对生物启发式和精准医疗需求的不断增长，肽类药物凭藉其安全性、特异性和广泛的治疗潜力，正在成为现代医疗保健的关键解决方案。

2024年，品牌胜肽类药物市占率预计将达到69.2%，这主要得益于其对创新、高特异性和已证实的临床疗效的重视。这些疗法在治疗复杂和慢性疾病方面越来越受欢迎，因为精准标靶和最小的脱靶效应至关重要。品牌胜肽类药物受益于强大的研发管线、持续的製剂改良和先进的递送机制，从而提升了患者的治疗效果和疗效的可靠性。

由于胜肽类药物稳定性差、口服生物利用度低，静脉注射、皮下注射或肌肉注射成为首选给药途径，因此，2024年肠外给药市场规模预计将达到308亿美元。肠外给药可确保药物快速吸收、剂量精准，并能有效治疗代谢失调、癌症及罕见内分泌疾病等关键适应症。

预计到2024年，北美肽类药物市场将占据42.1%的份额。该地区的成长得益于先进的生物製药基础设施、早期监管审批、强劲的研发投入以及癌症、代谢紊乱和罕见患者病率的上升。美国和加拿大等国家品牌化和创新胜肽类药物的开发，支撑了对标靶性强、低毒性治疗的需求。

全球胜肽类药物市场的主要参与者包括诺和诺德、PolyPeptide Group、Rhythm Pharmaceuticals、Ascendis Pharma、Zydus Lifesciences、Ferring Pharmaceuticals、阿斯特捷利康、X-GEN Pharmaceuticals、礼来公司、Repligen Corporation、赛诺菲、安进、百时施贵克、PeptiDam、PeptiDam、PeptiDam、PeptiDam、PeptiDam、PeptiDam、PeptiDam、PeptiDam、PeptiD这些公司正积极采取各种策略，例如投资研发以开发新型胜肽製剂、与生物技术新创公司合作以加速创新，以及建立策略联盟以实现全球分销。许多公司致力于拓展产品组合，以涵盖罕见疾病和慢性病领域，同时提升高纯度胜肽的生产能力。市场参与者正日益利用数位化平台和人工智慧技术进行精准药物研发、病患监测和真实世界资料收集。

目录

第一章：方法论与范围

第二章：执行概要

第三章：行业洞察

• 产业生态系分析
  • 供应商格局
  • 每个阶段的价值增加
  • 影响价值链的因素
• 产业影响因素
  • 成长驱动因素
    • 癌症发生率不断上升
    • 代谢和内分泌疾病发生率上升
    • 加大对新型药物研发的投入
    • 肽类药物的技术进步
  • 产业陷阱与挑战
    • 药品审批有严格的监理要求
    • 药物研发成本高昂
  • 市场机会
    • 肽-药物偶联物和放射性标记肽的创新
    • 扩大口服和长效胜肽製剂的供应
• 成长潜力分析
• 监管环境
• 未来市场趋势
• 技术格局
  • 目前技术
  • 新兴技术
• 专利分析
• 管道分析
• 波特的分析
• PESTEL 分析

第四章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 关键进展
  • 併购
  • 伙伴关係与合作
  • 新产品发布
  • 扩张计划

第五章：市场估算与预测：依类型划分，2021-2034年

• 主要趋势
• 品牌胜肽
• 通用胜肽

第六章：市场估算与预测：依应用领域划分，2021-2034年

• 主要趋势
• 代谢和内分泌紊乱
• 癌症
• 心血管疾病
• 胃肠道疾病
• 中枢神经系统疾病
• 呼吸系统疾病
• 疼痛管理
• 其他应用

第七章：市场估计与预测：依给药途径划分，2021-2034年

• 主要趋势
• 肠外
• 口服
• 其他给药途径

第八章：市场估算与预测：依製造商类型划分，2021-2034年

• 主要趋势
• 内部
• 外包

第九章：市场估算与预测：基于合成技术，2021-2034年

• 主要趋势
• 液相肽合成（LPPS）
• 固相胜肽合成（SPPS）
• 混合技术

第十章：市场估计与预测：依最终用途划分，2021-2034年

• 主要趋势
• 医院和诊所
• 製药和生物技术公司
• 其他最终用途

第十一章：市场估计与预测：按地区划分，2021-2034年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十二章：公司简介

• Amgen
• Ascendis Pharma
• AstraZeneca
• Bristol-Myers Squibb
• Eli Lilly and Company
• Ferring Pharmaceuticals
• Merck & Co.
• Novo Nordisk
• PeptiDream
• PolyPeptide Group
• Repligen Corporation
• Rhythm Pharmaceuticals
• Sanofi
• X-GEN Pharmaceuticals
• Zydus Lifesciences

The Global Peptide Therapeutics Market was valued at USD 46.4 billion in 2024 and is estimated to grow at a CAGR of 8.1% to reach USD 100 billion by 2034.

The increasing prevalence of chronic and lifestyle-related diseases, including diabetes, cancer, and obesity, is a significant growth driver. Peptide therapeutics, composed of short chains of amino acids, target specific molecular pathways, offering high efficacy and reduced side effects compared to conventional therapies. These treatments are applied across diverse therapeutic areas such as metabolic disorders, cardiovascular diseases, gastrointestinal conditions, infectious diseases, cancer, and rare genetic disorders. The integration of electronic health records, AI-based clinical decision-making tools, and real-world evidence platforms is reshaping the development, monitoring, and prescription of peptide therapies. Government programs and public-private partnerships enhancing access to molecular diagnostics, personalized medicine, and rare disease treatments further accelerate growth. With rising demand for biologically inspired and precision medicines, peptide therapeutics are emerging as critical solutions in modern healthcare due to their safety, specificity, and wide-ranging therapeutic potential.

The branded peptides segment held a 69.2% share in 2024, driven by its strong focus on innovation, high specificity, and proven clinical efficacy. These therapies are increasingly preferred for the treatment of complex and chronic conditions, where precise targeting and minimal off-target effects are essential. Branded peptides benefit from robust research and development pipelines, continuous formulation improvements, and advanced delivery mechanisms, which enhance patient outcomes and therapeutic reliability.

The parenteral segment generated USD 30.8 billion in 2024, owing to the poor stability and low oral bioavailability of peptides, making intravenous, subcutaneous, or intramuscular administration the preferred delivery method. Parenteral delivery ensures rapid absorption, accurate dosing, and high efficacy for critical indications such as metabolic disorders, cancer, and rare endocrine conditions.

North America Peptide Therapeutics Market held a 42.1% share in 2024. Growth in the region is fueled by advanced biopharmaceutical infrastructure, early regulatory approvals, strong R&D investments, and the rising prevalence of cancer, metabolic disorders, and rare diseases. The development of branded and innovative peptide therapies in countries like the U.S. and Canada supports demand for targeted, low-toxicity treatments.

Key players in the Global Peptide Therapeutics Market include Novo Nordisk, PolyPeptide Group, Rhythm Pharmaceuticals, Ascendis Pharma, Zydus Lifesciences, Ferring Pharmaceuticals, AstraZeneca, X-GEN Pharmaceuticals, Eli Lilly and Company, Repligen Corporation, Sanofi, Amgen, Bristol-Myers Squibb, PeptiDream, and Merck & Co. Companies in the Peptide Therapeutics Market are adopting strategies such as investing in research and development to create novel peptide formulations, collaborating with biotech startups to accelerate innovation, and forming strategic alliances for global distribution. Many firms focus on expanding their product portfolios to cover rare and chronic diseases while enhancing manufacturing capabilities for high-purity peptides. Market participants are increasingly leveraging digital platforms and AI for precision drug development, patient monitoring, and real-world data collection.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumption and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Type trends
  • 2.2.3 Application trends
  • 2.2.4 Route of administration trends
  • 2.2.5 Manufacturer type trends
  • 2.2.6 Synthesis technology trends
  • 2.2.7 End use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factor affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cancer
    • 3.2.1.2 Rising incidences of metabolic & endocrine disorders
    • 3.2.1.3 Increasing investments in research and development of novel drugs
    • 3.2.1.4 Technological advancement in peptide therapeutics
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory requirements for drug approval
    • 3.2.2.2 High cost for drug development
  • 3.2.3 Market opportunities
    • 3.2.3.1 Innovation in peptide-drug conjugates and radiolabelled peptides
    • 3.2.3.2 Expansion of oral and long-acting peptide formulations
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Future market trends
• 3.6 Technological landscape
  • 3.6.1 Current technologies
  • 3.6.2 Emerging technologies
• 3.7 Patent analysis
• 3.8 Pipeline analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Branded peptides
• 5.3 Generic peptides

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Metabolic & endocrine disorders
• 6.3 Cancer
• 6.4 Cardiovascular disorders
• 6.5 Gastrointestinal disorders
• 6.6 Central nervous system disorders
• 6.7 Respiratory disorders
• 6.8 Pain management
• 6.9 Other applications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Parenteral
• 7.3 Oral
• 7.4 Other route of administration

Chapter 8 Market Estimates and Forecast, By Manufacturer Type, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 In-house
• 8.3 Outsourced

Chapter 9 Market Estimates and Forecast, By Synthesis Technology, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Liquid phase peptide synthesis (LPPS)
• 9.3 Solid phase peptide synthesis (SPPS)
• 9.4 Hybrid technology

Chapter 10 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 Hospitals and clinics
• 10.3 Pharmaceutical and biotechnology companies
• 10.4 Other end use

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 11.1 Key trends
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 Netherlands
• 11.4 Asia Pacific
  • 11.4.1 China
  • 11.4.2 Japan
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 South Korea
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Argentina
• 11.6 Middle East and Africa
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 UAE

Chapter 12 Company Profiles

• 12.1 Amgen
• 12.2 Ascendis Pharma
• 12.3 AstraZeneca
• 12.4 Bristol-Myers Squibb
• 12.5 Eli Lilly and Company
• 12.6 Ferring Pharmaceuticals
• 12.7 Merck & Co.
• 12.8 Novo Nordisk
• 12.9 PeptiDream
• 12.10 PolyPeptide Group
• 12.11 Repligen Corporation
• 12.12 Rhythm Pharmaceuticals
• 12.13 Sanofi
• 12.14 X-GEN Pharmaceuticals
• 12.15 Zydus Lifesciences